Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bruker Cellular Analysis, Inc.BLI · Entity 109250 | Director | March 11, 2021 | March 15, 2021 |
| GoPro, Inc.GPRO · Entity 6232 | Director | February 17, 2017 | February 22, 2017 |
| SLB LIMITED/NVSLB · Entity 2936 | Director | October 26, 2017 | December 03, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bruker Cellular Analysis, Inc.
Report date March 11, 2021 · Filed March 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Marks Family Trust | 1,114,142 |
Last balance in matching sequence
After 2021-03-11 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2021-03-11 · Sale · Disposed 6,100 · Balance 1,136,302 F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.70 to $54.6950. The reporting person undertakes to provide Berkeley Lights, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: As trustee of the Marks Family Trust (the "Trust"), Mr. Marks may be deemed to beneficially own the shares held by the Trust. Mr. Marks disclaims beneficial ownership of the shares held by the Trust except to the extent of his pecuniary interest therein. Row 2 · 2021-03-11 · Sale · Disposed 22,160 · Balance 1,114,142 F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.70 to $55.53. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: As trustee of the Marks Family Trust (the "Trust"), Mr. Marks may be deemed to beneficially own the shares held by the Trust. Mr. Marks disclaims beneficial ownership of the shares held by the Trust except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.70 to $54.6950. The reporting person undertakes to provide Berkeley Lights, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: As trustee of the Marks Family Trust (the "Trust"), Mr. Marks may be deemed to beneficially own the shares held by the Trust. Mr. Marks disclaims beneficial ownership of the shares held by the Trust except to the extent of his pecuniary interest therein.
F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.70 to $55.53. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
GoPro, Inc.
Report date February 17, 2017 · Filed February 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 35,401 |
Reported balance
After 2017-02-17 transaction · row 1
1 source rowRow 1 · 2017-02-17 · Sale · Disposed 30,000 · Balance 35,401 F1: The price reported is a weighted average price. These shares of Class A Common Stock were sold in multiple transactions at sales prices ranging from $9.185 to $9.245, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Marks Family Trust | 5,438 |
Reported balance
Holding disclosure · report date 2017-02-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,438 F2: Mr. Marks and his spouse are co-trustees of the Marks Family Trust. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Riverwood Capital L.P. | 39,393 |
Reported balance
Holding disclosure · report date 2017-02-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 39,393 F3: Represents only shares of Class A Common Stock in which Mr. Marks may be deemed to have a pecuniary interest. F4: Includes 39,393 shares of Class A Common Stock held by Riverwood LP in escrow for the benefit of Mr. Marks, subject to release in accordance with the terms of such fund's limited partnership agreement. Mr. Marks has dispositive power over the shares of Class A Common Stock held for his benefit by Riverwood LP and bears the investment risk of such shares of Class A Common Stock. F5: Riverwood Capital GP Ltd. ("Riverwood GP") is the general partner of Riverwood LP. Mr. Marks is Chief Executive Officer, one of three directors, one of six members of the investment committee and one of a number of shareholders of Riverwood GP. Mr. Marks does not have voting or dispositive power over the shares of Class A Common Stock held by Riverwood GP as Chief Executive Officer; such powers reside with the directors, the investment committee and/or the shareholders. Mr. Marks disclaims beneficial ownership of shares of Class A Common Stock held by Riverwood LP, Riverwood GP and the Funds, except to the extent of Mr. Marks's pecuniary interest therein. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy WB Investors, LLC | 49,607 |
Reported balance
Holding disclosure · report date 2017-02-17 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 49,607 F6: Mr. Marks is Manager of WB Investors, LLC ("WB"). The members of WB are Epping Investment Holdings, LLC, which Mr. Marks controls, and certain trusts controlled by Mr. Marks and for the benefit of Mr. Marks and members of his immediate family. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares of Class A Common Stock were sold in multiple transactions at sales prices ranging from $9.185 to $9.245, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: Mr. Marks and his spouse are co-trustees of the Marks Family Trust.
F3: Represents only shares of Class A Common Stock in which Mr. Marks may be deemed to have a pecuniary interest.
F4: Includes 39,393 shares of Class A Common Stock held by Riverwood LP in escrow for the benefit of Mr. Marks, subject to release in accordance with the terms of such fund's limited partnership agreement. Mr. Marks has dispositive power over the shares of Class A Common Stock held for his benefit by Riverwood LP and bears the investment risk of such shares of Class A Common Stock.
F5: Riverwood Capital GP Ltd. ("Riverwood GP") is the general partner of Riverwood LP. Mr. Marks is Chief Executive Officer, one of three directors, one of six members of the investment committee and one of a number of shareholders of Riverwood GP. Mr. Marks does not have voting or dispositive power over the shares of Class A Common Stock held by Riverwood GP as Chief Executive Officer; such powers reside with the directors, the investment committee and/or the shareholders. Mr. Marks disclaims beneficial ownership of shares of Class A Common Stock held by Riverwood LP, Riverwood GP and the Funds, except to the extent of Mr. Marks's pecuniary interest therein.
F6: Mr. Marks is Manager of WB Investors, LLC ("WB"). The members of WB are Epping Investment Holdings, LLC, which Mr. Marks controls, and certain trusts controlled by Mr. Marks and for the benefit of Mr. Marks and members of his immediate family.
SLB LIMITED/NV
Report date October 26, 2017 · Filed December 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 Par Value Per ShareSEC Table I · non-derivative | Indirectby Trust | 84,205 |
Reported balance
After 2017-10-26 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2017-10-26 · Purchase · Acquired 16,000 · Balance 84,205 F1: Held by the Marks Family Trust UA DTD 07/07/2000, of which the reporting person is a co-trustee and a co-beneficiary. |
Filing footnotes · ownership attribution and instrument terms
F1: Held by the Marks Family Trust UA DTD 07/07/2000, of which the reporting person is a co-trustee and a co-beneficiary.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
KLA CORP
Report date May 11, 2006 · Filed May 15, 2006
Section 16 reporting ended · disclosed 2006-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock-Restricted Stock UnitsSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2006-05-11 transaction · row 1
1 source rowRow 1 · 2006-05-11 · Disposition to issuer · Disposed 1,000 · Balance 0 F1: Unvested Restricted Stock Units forfeited upon resignation. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.86 · Expires 2013-05-02 | Direct | 1,250 |
Reported balance
Holding disclosure · report date 2006-05-11 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 1,250 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.99 · Expires 2012-11-04 | Direct | 1,250 |
Reported balance
Holding disclosure · report date 2006-05-11 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 1,250 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.35 · Expires 2012-08-02 | Direct | 2,500 |
Reported balance
Holding disclosure · report date 2006-05-11 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 2,500 F2: Option expiration date was reported incorrectly on the original Form 4. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.98 · Expires 2013-01-31 | Direct | 1,250 |
Reported balance
Holding disclosure · report date 2006-05-11 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 1,250 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.44 · Expires 2013-11-05 | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2006-05-11 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 10,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Unvested Restricted Stock Units forfeited upon resignation.
F2: Option expiration date was reported incorrectly on the original Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2021 Filed Mar 15, 2021 17:51 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | SaleCommon Stock | 22,160 | $55.19 | $1,222,977.16 |
DisclosureSEC source: 0000899243-21-011660 · doc4.xml · nonDerivative · entry 2 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Marks Family Trust Disclosed balance after: 1,114,142 F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.70 to $55.53. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: As trustee of the Marks Family Trust (the "Trust"), Mr. Marks may be deemed to beneficially own the shares held by the Trust. Mr. Marks disclaims beneficial ownership of the shares held by the Trust except to the extent of his pecuniary interest therein. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 17:51 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | SaleCommon Stock | 6,100 | $54.19 | $330,534.60 |
DisclosureSEC source: 0000899243-21-011660 · doc4.xml · nonDerivative · entry 1 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Marks Family Trust Disclosed balance after: 1,136,302 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.70 to $54.6950. The reporting person undertakes to provide Berkeley Lights, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: As trustee of the Marks Family Trust (the "Trust"), Mr. Marks may be deemed to beneficially own the shares held by the Trust. Mr. Marks disclaims beneficial ownership of the shares held by the Trust except to the extent of his pecuniary interest therein. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 18:43 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | SaleCommon Stock | 54,190 | $53.29 | $2,887,524.99 |
DisclosureSEC source: 0000899243-21-011181 · doc4.xml · nonDerivative · entry 5 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Marks Family Trust Disclosed balance after: 1,142,402 F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.06 to $54.03. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: As trustee of the Marks Family Trust (the "Trust"), Mr. Marks may be deemed to beneficially own the shares held by the Trust. Mr. Marks disclaims beneficial ownership of the shares held by the Trust except to the extent of his pecuniary interest therein. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 18:43 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | SaleCommon Stock | 45,810 | $52.81 | $2,419,088.67 |
DisclosureSEC source: 0000899243-21-011181 · doc4.xml · nonDerivative · entry 4 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Marks Family Trust Disclosed balance after: 1,196,592 F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $52.06 to $53.05. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: As trustee of the Marks Family Trust (the "Trust"), Mr. Marks may be deemed to beneficially own the shares held by the Trust. Mr. Marks disclaims beneficial ownership of the shares held by the Trust except to the extent of his pecuniary interest therein. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 18:43 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | SaleCommon Stock | 300 | $54.62 | $16,385.01 |
DisclosureSEC source: 0000899243-21-011181 · doc4.xml · nonDerivative · entry 3 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Marks Family Trust Disclosed balance after: 1,242,402 F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.57 to $54.65. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: As trustee of the Marks Family Trust (the "Trust"), Mr. Marks may be deemed to beneficially own the shares held by the Trust. Mr. Marks disclaims beneficial ownership of the shares held by the Trust except to the extent of his pecuniary interest therein. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 18:43 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | SaleCommon Stock | 15,238 | $53.84 | $820,354.49 |
DisclosureSEC source: 0000899243-21-011181 · doc4.xml · nonDerivative · entry 2 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Marks Family Trust Disclosed balance after: 1,242,702 F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.54 to $54.48. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: As trustee of the Marks Family Trust (the "Trust"), Mr. Marks may be deemed to beneficially own the shares held by the Trust. Mr. Marks disclaims beneficial ownership of the shares held by the Trust except to the extent of his pecuniary interest therein. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 18:43 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | SaleCommon Stock | 14,462 | $53.30 | $770,785.55 |
DisclosureSEC source: 0000899243-21-011181 · doc4.xml · nonDerivative · entry 1 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Marks Family Trust Disclosed balance after: 1,257,940 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $52.54 to $53.5347. The reporting person undertakes to provide Berkeley Lights, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: As trustee of the Marks Family Trust (the "Trust"), Mr. Marks may be deemed to beneficially own the shares held by the Trust. Mr. Marks disclaims beneficial ownership of the shares held by the Trust except to the extent of his pecuniary interest therein. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 21:40 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | SaleCommon Stock | 505 | $62.22 | $31,421.35 |
DisclosureSEC source: 0000899243-21-010221 · doc4.xml · nonDerivative · entry 2 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Marks Family Trust Disclosed balance after: 1,272,402 F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $62.12 to $62.25. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: As trustee of the Marks Family Trust (the "Trust"), Mr. Marks may be deemed to beneficially own the shares held by the Trust. Mr. Marks disclaims beneficial ownership of the shares held by the Trust except to the extent of his pecuniary interest therein. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 21:40 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | SaleCommon Stock | 1,235 | $61.26 | $75,661.41 |
DisclosureSEC source: 0000899243-21-010221 · doc4.xml · nonDerivative · entry 1 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Marks Family Trust Disclosed balance after: 1,272,907 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $61.00 to $61.77. The reporting person undertakes to provide Berkeley Lights, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: As trustee of the Marks Family Trust (the "Trust"), Mr. Marks may be deemed to beneficially own the shares held by the Trust. Mr. Marks disclaims beneficial ownership of the shares held by the Trust except to the extent of his pecuniary interest therein. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 21:52 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | SaleCommon Stock | 1,782 | $64.61 | $115,126.47 |
DisclosureSEC source: 0000899243-21-009691 · doc4.xml · nonDerivative · entry 4 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Mark Family Trust Disclosed balance after: 1,274,142 F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $62.75 to $63.72. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F6 · balance_after: Reflects receipt of 1,314,142 shares received in a pro rata distribution in kind, which was exempt from reporting under Rule 16a-9. F2 · ownership.nature: As trustee of the Marks Family Trust (the "Trust"), Mr. Marks may be deemed to beneficially own the shares held by the Trust. Mr. Marks disclaims beneficial ownership of the shares held by the Trust except to the extent of his pecuniary interest therein. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 21:52 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | SaleCommon Stock | 6,210 | $63.16 | $392,200.62 |
DisclosureSEC source: 0000899243-21-009691 · doc4.xml · nonDerivative · entry 3 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Mark Family Trust Disclosed balance after: 1,275,924 F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $62.75 to $63.72. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F6 · balance_after: Reflects receipt of 1,314,142 shares received in a pro rata distribution in kind, which was exempt from reporting under Rule 16a-9. F2 · ownership.nature: As trustee of the Marks Family Trust (the "Trust"), Mr. Marks may be deemed to beneficially own the shares held by the Trust. Mr. Marks disclaims beneficial ownership of the shares held by the Trust except to the extent of his pecuniary interest therein. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 21:52 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | SaleCommon Stock | 12,008 | $62.22 | $747,143.76 |
DisclosureSEC source: 0000899243-21-009691 · doc4.xml · nonDerivative · entry 2 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Mark Family Trust Disclosed balance after: 1,282,134 F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $61.74 to $62.71. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F6 · balance_after: Reflects receipt of 1,314,142 shares received in a pro rata distribution in kind, which was exempt from reporting under Rule 16a-9. F2 · ownership.nature: As trustee of the Marks Family Trust (the "Trust"), Mr. Marks may be deemed to beneficially own the shares held by the Trust. Mr. Marks disclaims beneficial ownership of the shares held by the Trust except to the extent of his pecuniary interest therein. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:52 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | SaleCommon Stock | 20,000 | $61.93 | $1,238,598.00 |
DisclosureSEC source: 0000899243-21-009691 · doc4.xml · nonDerivative · entry 1 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Mark Family Trust Disclosed balance after: 1,294,142 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $61.195 to $62.60. The reporting person undertakes to provide Berkeley Lights, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F6 · balance_after: Reflects receipt of 1,314,142 shares received in a pro rata distribution in kind, which was exempt from reporting under Rule 16a-9. F2 · ownership.nature: As trustee of the Marks Family Trust (the "Trust"), Mr. Marks may be deemed to beneficially own the shares held by the Trust. Mr. Marks disclaims beneficial ownership of the shares held by the Trust except to the extent of his pecuniary interest therein. Read SEC document |
| December 10, 2020 Filed Dec 18, 2020 20:28 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | SaleCommon Stock | 55,162 | $82.56 | $4,554,174.72 |
DisclosureSEC source: 0000899243-20-034553 · doc4.xml · nonDerivative · entry 1 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,700,007 F1 · ownership.nature: Following the transactions reported herein, consists of 2,860,225 shares held by Walden Riverwood Ventures, L.P. ("Walden") and 839,782 shares held by WRV II, L.P. ("WRV II"). Mr. Marks is a member of the investment committee of Walden Riverwood GP, LLC ("Walden GP"), which is the general partner of Walden. Mr. Marks is a member of the investment committee of WRV GP II, LLC ("WRV GP"), which is the general partner of WRV II. As a result, Mr. Marks may be deemed to beneficially own the shares held by Walden and WRV II. Mr. Marks disclaims beneficial ownership of the shares held by Walden and WRVII except to the extent of his pecuniary interest therein. Walden and WRV II are filing separate statements of changes in beneficial ownership on Forms 4. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 14:08 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | SaleCommon Stock | 362,586 | $82.56 | $29,935,100.16 |
DisclosureSEC source: 0000899243-20-032132 · doc4.xml · nonDerivative · entry 1 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,755,169 F1 · ownership.nature: Following the transactions reported herein, consists of 2,902,867 shares held by Walden Riverwood Ventures, L.P. ("Walden") and 852,302 shares held by WRV II, L.P. ("WRV II"). Mr. Marks is a member of the investment committee of Walden Riverwood GP, LLC ("Walden GP"), which is the general partner of Walden. Mr. Marks is a member of the investment committee of WRV GP II, LLC ("WRV GP"), which is the general partner of WRV II. As a result, Mr. Marks may be deemed to beneficially own the shares held by Walden and WRV II. Mr. Marks disclaims beneficial ownership of the shares held by Walden and WRVII except to the extent of his pecuniary interest therein. Walden and WRV II are filing separate statements of changes in beneficial ownership on Forms 4. Read SEC document |
| July 16, 2020 Filed Jul 20, 2020 21:45 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | ConversionSeries E Preferred Stock · Derivative | 19,230 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019727 · doc4.xml · derivative · entry 7 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Marks Family Trust Disclosed balance after: 0 Underlying: Common Stock · 19,230 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering F1 · derivative.exercise_date: Each share of Preferred Stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering F1 · derivative.expiration_date: Each share of Preferred Stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering F3 · ownership.nature: As trustee of the Marks Family Trust (the "Trust"), Mr. Marks may be deemed to beneficially own the shares held by the Trust. Mr. Marks disclaims beneficial ownership of the shares held by the Trust except to the extent of his pecuniary interest therein. Read SEC document |
| July 16, 2020 Filed Jul 20, 2020 21:45 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | ConversionSeries E Preferred Stock · Derivative | 191,655 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019727 · doc4.xml · derivative · entry 6 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 191,655 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering F1 · derivative.exercise_date: Each share of Preferred Stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering F1 · derivative.expiration_date: Each share of Preferred Stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering F5 · ownership.nature: Mr. Marks is a member of the investment committee of WRV GP, which is the general partner of WRV II. As a result, Mr. Marks may be deemed to beneficially own the shares held by the WRV II. Mr. Marks disclaims beneficial ownership of the shares held by WRV II and Walden except to the extent of his pecuniary interest therein. WRV II and Walden are filing separate statements of initial change in beneficial ownership on Forms 4. Read SEC document |
| July 16, 2020 Filed Jul 20, 2020 21:45 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | ConversionSeries D Preferred Stock · Derivative | 742,942 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019727 · doc4.xml · derivative · entry 5 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 742,942 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering F1 · derivative.exercise_date: Each share of Preferred Stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering F1 · derivative.expiration_date: Each share of Preferred Stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering F5 · ownership.nature: Mr. Marks is a member of the investment committee of WRV GP, which is the general partner of WRV II. As a result, Mr. Marks may be deemed to beneficially own the shares held by the WRV II. Mr. Marks disclaims beneficial ownership of the shares held by WRV II and Walden except to the extent of his pecuniary interest therein. WRV II and Walden are filing separate statements of initial change in beneficial ownership on Forms 4. Read SEC document |
| July 16, 2020 Filed Jul 20, 2020 21:45 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | ConversionSeries C Preferred Stock · Derivative | 853,242 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019727 · doc4.xml · derivative · entry 4 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 853,242 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering F1 · derivative.exercise_date: Each share of Preferred Stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering F1 · derivative.expiration_date: Each share of Preferred Stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering F4 · ownership.nature: Mr. Marks is a member of the investment committee of Walden GP, which is the general partner of Walden. As a result, Mr. Marks may be deemed to beneficially own the shares held by Walden. Mr. Marks disclaims beneficial ownership of the shares held by Walden except to the extent of his pecuniary interest therein. Walden and Walden GP are filing separate statements of change in beneficial ownership on Forms 4. Read SEC document |
| July 16, 2020 Filed Jul 20, 2020 21:45 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | ConversionSeries B Preferred Stock · Derivative | 2,329,916 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019727 · doc4.xml · derivative · entry 3 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,329,916 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering F1 · derivative.exercise_date: Each share of Preferred Stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering F1 · derivative.expiration_date: Each share of Preferred Stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering F4 · ownership.nature: Mr. Marks is a member of the investment committee of Walden GP, which is the general partner of Walden. As a result, Mr. Marks may be deemed to beneficially own the shares held by Walden. Mr. Marks disclaims beneficial ownership of the shares held by Walden except to the extent of his pecuniary interest therein. Walden and Walden GP are filing separate statements of change in beneficial ownership on Forms 4. Read SEC document |
| July 16, 2020 Filed Jul 20, 2020 21:45 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | ConversionCommon Stock | 19,230 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019727 · doc4.xml · nonDerivative · entry 2 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Marks Family Trust Disclosed balance after: 19,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering F3 · ownership.nature: As trustee of the Marks Family Trust (the "Trust"), Mr. Marks may be deemed to beneficially own the shares held by the Trust. Mr. Marks disclaims beneficial ownership of the shares held by the Trust except to the extent of his pecuniary interest therein. Read SEC document |
| July 16, 2020 Filed Jul 20, 2020 21:45 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | ConversionCommon Stock | 4,117,755 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019727 · doc4.xml · nonDerivative · entry 1 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,117,755 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering F2 · ownership.nature: Following the transactions reported herein, consists of 3,183,158 shares held by Walden Riverwood Ventures, L.P. ("Walden") and 934,597 shares held by WRV II, L.P. ("WRV II"). Mr. Marks is a member of the investment committee of Walden Riverwood GP, LLC ("Walden GP"), which is the general partner of Walden. Mr. Marks is a member of the investment committee of WRV GP II, LLC ("WRV GP"), which is the general partner of WRV II. As a result, Mr. Marks may be deemed to beneficially own the shares held by Walden and WRV II. Mr. Marks disclaims beneficial ownership of the shares held by Walden and WRVII except to the extent of his pecuniary interest therein. Walden and WRV II are filing separate statements of changes in beneficial ownership on Forms 4. Read SEC document |
| September 06, 2018 Filed Sep 7, 2018 16:12 UTC | SLB LIMITED/NV SLB · Entity 2936 | PurchaseCommon Stock, $0.01 Par Value Per Share | 8,000 | $60.31 | $482,480.00 |
DisclosureSEC source: 0001127602-18-027016 · form4.xml · nonDerivative · entry 1 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 68,021 F1 · ownership.nature: Held by the Marks Family Trust UA DTD 07/07/2000, of which the reporting person is a co-trustee and a co-beneficiary. Read SEC document |
| May 01, 2018 Filed May 1, 2018 21:21 UTC | SLB LIMITED/NV SLB · Entity 2936 | GrantCommon Stock, $0.01 Par Value Per Share | 2,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-015778 · form4.xml · nonDerivative · entry 1 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Marks Family Trust Disclosed balance after: 60,021 F1 · shares: Pursuant to Schlumberger Limited Stock and Deferral Plan for Non-Employee Directors. F2 · ownership.nature: Held by the Marks Family Trust UA DTD 07/07/2000, of which the reporting person is a co-trustee and a co-beneficiary. Includes stock previously held by limited liability companies controlled by the reporting person. Read SEC document |
| October 26, 2017 Filed Dec 3, 2018 22:43 UTC | SLB LIMITED/NV SLB · Entity 2936 | PurchaseCommon Stock, $0.01 Par Value Per Share | 16,000 | $63.56 | $1,016,960.00 |
DisclosureSEC source: 0001127602-18-035015 · form4.xml · nonDerivative · entry 1 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 84,205 F1 · ownership.nature: Held by the Marks Family Trust UA DTD 07/07/2000, of which the reporting person is a co-trustee and a co-beneficiary. Read SEC document |
| August 11, 2017 Filed Aug 14, 2017 21:44 UTC | SLB LIMITED/NV SLB · Entity 2936 | PurchaseCommon Stock, $0.01 Par Value Per Share | 8,000 | $64.20 | $513,592.00 |
DisclosureSEC source: 0001127602-17-025594 · form4.xml · nonDerivative · entry 1 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by trust Disclosed balance after: 18,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $64.199 to $64.2000. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff or a security holder of the issuer, full information regarding the number of shares and prices at which the trades were effected. F2 · ownership.nature: Held by the Marks Family Trust UA DTD 07/07/2000, of which the reporting person is a co-trustee and a co-beneficiary. Read SEC document |
| May 01, 2017 Filed May 1, 2017 21:13 UTC | SLB LIMITED/NV SLB · Entity 2936 | GrantCommon Stock, $0.01 Par Value Per Share | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016100 · form4.xml · nonDerivative · entry 1 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by limited liability company Disclosed balance after: 39,250 F1 · shares: Pursuant to Schlumberger Limited Stock and Deferral Plan for Non-Employee Directors. F2 · ownership.nature: All held by Epping LLC or WB Investors LLC, both of which are controlled by the reporting person. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 21:03 UTC | GoPro, Inc. GPRO · Entity 6232 | SaleClass A Common Stock | 30,000 | $9.22 | $276,510.00 |
DisclosureSEC source: 0001209191-17-013554 · doc4.xml · nonDerivative · entry 1 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,401 F1 · price: The price reported is a weighted average price. These shares of Class A Common Stock were sold in multiple transactions at sales prices ranging from $9.185 to $9.245, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 11, 2006 Filed May 15, 2006 20:07 UTC | KLA CORP KLAC · Entity 2838 | Disposition to issuerCommon Stock-Restricted Stock Units | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000319201-06-000047 · edgardoc.xml · nonDerivative · entry 1 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Unvested Restricted Stock Units forfeited upon resignation. Read SEC document |
| May 09, 2006 Filed May 9, 2006 23:42 UTC | KLA CORP KLAC · Entity 2838 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $48.83 Strike: $44.76 | $122,075.00 |
DisclosureSEC source: 0000319201-06-000045 · edgardoc.xml · derivative · entry 10 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2015-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2006 Filed May 9, 2006 23:42 UTC | KLA CORP KLAC · Entity 2838 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $48.68 Strike: $40.68 | $121,700.00 |
DisclosureSEC source: 0000319201-06-000045 · edgardoc.xml · derivative · entry 9 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2014-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2006 Filed May 9, 2006 23:42 UTC | KLA CORP KLAC · Entity 2838 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $48.45 Strike: $40.24 | $121,125.00 |
DisclosureSEC source: 0000319201-06-000045 · edgardoc.xml · derivative · entry 8 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2015-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2006 Filed May 9, 2006 23:42 UTC | KLA CORP KLAC · Entity 2838 | SaleCommon Stock | 2,500 | $48.83 | $122,075.00 |
DisclosureSEC source: 0000319201-06-000045 · edgardoc.xml · nonDerivative · entry 6 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 09, 2006 Filed May 9, 2006 23:42 UTC | KLA CORP KLAC · Entity 2838 | SaleCommon Stock | 2,500 | $48.68 | $121,700.00 |
DisclosureSEC source: 0000319201-06-000045 · edgardoc.xml · nonDerivative · entry 5 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Read SEC document |
| May 09, 2006 Filed May 9, 2006 23:42 UTC | KLA CORP KLAC · Entity 2838 | SaleCommon Stock | 2,500 | $48.45 | $121,125.00 |
DisclosureSEC source: 0000319201-06-000045 · edgardoc.xml · nonDerivative · entry 4 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| May 09, 2006 Filed May 9, 2006 23:42 UTC | KLA CORP KLAC · Entity 2838 | Exercise / conversionCommon Stock | 2,500 | $40.24 | $100,600.00 |
DisclosureSEC source: 0000319201-06-000045 · edgardoc.xml · nonDerivative · entry 3 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2006 Filed May 9, 2006 23:42 UTC | KLA CORP KLAC · Entity 2838 | Exercise / conversionCommon Stock | 2,500 | $44.76 | $111,900.00 |
DisclosureSEC source: 0000319201-06-000045 · edgardoc.xml · nonDerivative · entry 2 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2006 Filed May 9, 2006 23:42 UTC | KLA CORP KLAC · Entity 2838 | Exercise / conversionCommon Stock | 2,500 | $40.68 | $101,700.00 |
DisclosureSEC source: 0000319201-06-000045 · edgardoc.xml · nonDerivative · entry 1 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2006 Filed May 3, 2006 21:37 UTC | KLA CORP KLAC · Entity 2838 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,250 | $0.00 Strike: $47.86 | $0.00 |
DisclosureSEC source: 0000319201-06-000043 · edgardoc.xml · derivative · entry 2 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires 2013-05-02 Read SEC document |
| January 31, 2006 Filed Feb 2, 2006 00:18 UTC | KLA CORP KLAC · Entity 2838 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,250 | $0.00 Strike: $51.98 | $0.00 |
DisclosureSEC source: 0000319201-06-000010 · edgardoc.xml · derivative · entry 2 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires 2013-01-31 Read SEC document |
| November 04, 2005 Filed Nov 8, 2005 00:05 UTC | KLA CORP KLAC · Entity 2838 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,250 | $0.00 Strike: $49.99 | $0.00 |
DisclosureSEC source: 0000319201-05-000156 · edgardoc.xml · derivative · entry 2 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires 2012-11-04 Read SEC document |
| November 04, 2005 Filed Nov 8, 2005 00:05 UTC | KLA CORP KLAC · Entity 2838 | GrantCommon Stock-Restricted Stock Units | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000319201-05-000156 · edgardoc.xml · nonDerivative · entry 1 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · security: Each restricted stock unit represents a contingent right to receive one share of KLAC common stock. F2 · price: The restricted stock units will fully vest one year from date of grant and will not be deliverable until three years from the date of grant. Read SEC document |
| August 02, 2005 Filed Aug 3, 2005 23:47 UTC | KLA CORP KLAC · Entity 2838 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $51.35 | $0.00 |
DisclosureSEC source: 0000319201-05-000076 · edgardoc.xml · derivative · entry 1 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2015-08-02 Read SEC document |
| August 02, 2005 Filed Aug 15, 2005 18:41 UTC Amendment | KLA CORP KLAC · Entity 2838 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $51.35 | $0.00 |
DisclosureSEC source: 0000319201-05-000102 · edgardoc.xml · derivative · entry 1 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2012-08-02 F1 · derivative.expiration_date: Option expiration date was reported incorrectly on the original Form 4. Read SEC document |
| May 11, 2005 Filed May 12, 2005 00:49 UTC | KLA CORP KLAC · Entity 2838 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $40.24 | $0.00 |
DisclosureSEC source: 0000319201-05-000042 · edgardoc.xml · derivative · entry 1 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2015-05-11 Read SEC document |
| January 25, 2005 Filed Jan 27, 2005 00:28 UTC | KLA CORP KLAC · Entity 2838 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $44.76 | $0.00 |
DisclosureSEC source: 0000319201-05-000014 · edgardoc.xml · derivative · entry 1 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2015-01-25 Read SEC document |
| October 18, 2004 Filed Oct 18, 2004 23:46 UTC | KLA CORP KLAC · Entity 2838 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $40.68 | $0.00 |
DisclosureSEC source: 0000319201-04-000150 · edgardoc.xml · derivative · entry 1 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2014-10-18 Read SEC document |
| November 05, 2003 Filed Nov 7, 2003 22:02 UTC | KLA CORP KLAC · Entity 2838 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $59.44 Strike: $59.44 | $297,200.00 |
DisclosureSEC source: 0000319201-03-000164 · edgardoc.xml · derivative · entry 2 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2013-11-05 Read SEC document |
| November 05, 2003 Filed Nov 7, 2003 22:02 UTC | KLA CORP KLAC · Entity 2838 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $59.44 Strike: $59.44 | $297,200.00 |
DisclosureSEC source: 0000319201-03-000164 · edgardoc.xml · derivative · entry 1 MARKS MICHAEL E · CIK 0001163715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2013-11-05 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.